ClinicalTrials.gg
CompletedNCT07105722Updated Jun 5, 2026

A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age

A Phase 1 interventional study of Pn-MAPS30plus and PCV20 in Pneumonia, Bacterial, sponsored by GlaxoSmithKline. Completed at 4 sites in Australia. Open to participants aged 50 Years to 64 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-06-05.

Sponsored by GlaxoSmithKline · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
127
Allocation
Randomized
Ages
50 Years to 64 Years
Sex
All
01

Study summary

This clinical study is designed to evaluate an investigational pneumococcal vaccine named Pn-MAPS30plus. The vaccine is designed to stimulate the immune system to produce antibodies against various serotypes of the S. pneumoniae bacteria, potentially aiding the body in fighting infection upon exposure. Pn-MAPS30plus aims to broaden protection by covering more serotypes than currently licensed pneumococcal vaccines. The study's purpose is to determine whether the vaccine is safe, well-tolerated, and effective in inducing immune responses against S. pneumoniae.

02

Conditions studied

  • Pneumonia, Bacterial

Browse trials for

Keywords

  • Streptococcus pneumoniae
  • Pn-MAPS30plus
  • 20 valent pneumococcal conjugate vaccine (PCV20)
03

In context

Pneumonia, Bacterial

153 studies on the registry are indexed under Pneumonia, Bacterial; 27 are open to participants now.

This study's enrollment of 127 is close to the median of 132 across 107 interventional studies indexed under Pneumonia, Bacterial.

Browse Pneumonia, Bacterial studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.
  2. Written or witnessed/thumb printed obtained from the participant prior to performance of any trial-specific procedure.
  3. Healthy male and female participants between and including 50 through 64 YOA at the time of Informed consent form (ICF) signature.
  4. Female participants of may be enrolled if they practice adequate and have a negative pregnancy test prior to study intervention administration.

Exclusion criteria

Exclusion Criteria:

  1. History of microbiologically proven Invasive Pneumococcal Disease (IPD) caused by S. pneumoniae within the past 3 years.
  2. History of any reaction or likely to be exacerbated by any component of the study intervention(s).
  3. Any confirmed or suspected or immunodeficient condition.
  4. Hypersensitivity to latex.
  5. Clinical conditions representing a to intramuscular vaccination, and blood collection.
  6. Documented history of (HIV)-positive participant.
  7. Acute or unstable chronic pulmonary, cardiovascular, hepatic or renal functional abnormality, or metabolic conditions as determined by the investigator.
  8. Recurrent history of uncontrolled neurological or any neuroinflammatory disorders.
  9. Any behavioural or cognitive impairment or psychiatric disease that, in the opinion of the investigator, may interfere with trial participation.
  10. History of potential immune-mediated disorders (pIMDs).
  11. Any other clinical condition that, might pose additional risk to the participant.
  12. Use of any or non-registered product other than the study interventions during the period beginning 30 days before the study intervention administration.
  13. History of previous vaccination with any pneumococcal vaccine.
  14. Receipt of blood or plasma products or immunoglobulins, from 90 days before study intervention administration, or planned receipt within 30 days of study intervention administration.
  15. Chronic administration of immune-modifying drugs (defined as more than 14 consecutive days in total) and/or planned use of long-acting immune-modifying treatments at any time up to the end of the trial.
  16. Pregnant or lactating female participant.
  17. History of chronic alcohol consumption and/or drug abuse, based on investigator judgment.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
127 participants (actual)

Study arms

  • Experimental
    Pn-MAPS30plus Group

    Participants receive a single dose of Pn-MAPS30plus on Day 1.

    Biological: Pn-MAPS30plus

  • Active comparator
    PCV20 Group

    Participants receive a single dose of PCV20 on Day 1.

    Combination Product: PCV20

Interventions

  • BiologicalPn-MAPS30plus

    The Pn-MAPS30plus vaccine will be administered intramuscularly.

  • Combination productPCV20

    The PCV20 vaccine will be administered intramuscularly.

06

What researchers measure

Primary outcomes

  1. Number of Participants with Each Solicited Administration Site (Local) Event

    Time frame: Day 1 (post-vaccination) to Day 7

  2. Number of Participants with Each Solicited Systemic Event

    Time frame: Day 1 (post-vaccination) to Day 7

  3. Number of Participants with Any Unsolicited Adverse Events (AEs)

    Time frame: Day 1 (post-vaccination) to Day 30

  4. Number of Participants with Serious AEs (SAEs), Adverse Events of Special Interest (AESIs) and AEs Leading to Withdrawal

    Time frame: Day 1 up to trial end (Month 6)

  5. Number of Participants with Hematological and Biochemical Laboratory Abnormalities

    Time frame: On Day 8

07

Study locations

4 sites
  • GSK Investigational Site
    Norwood, South Australia 5067, Australia
  • GSK Investigational Site
    Bayswater, Victoria 3153, Australia
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
  • GSK Investigational Site
    East Melbourne, Victoria 3002, Australia
08

References and documents

Individual participant data

Plan to share: Yes — Study Sponsor will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer to https://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: Anonymized IPD will be made available within 6 months of publication of primary, key secondary and safety results for studies in product with approved indication(s) or asset(s) with development terminated across all indications.

Access criteria: Anonymized IPD is shared with researchers whose proposals are approved by an Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension may be granted, when justified, for up to 6 months.

Data sharing details ↗ · www.gsk-studyregister.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2025 to primary completion in May 2026, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 4, 2025
First posted
Aug 6, 2025
StartActual
Aug 12, 2025
Primary completionActual
May 6, 2026
CompletionActual
May 6, 2026
Last update
Jun 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07105722
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Aug 12, 2025
Primary completion
May 6, 2026
Completion
May 6, 2026
Last update
Jun 5, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pn-MAPS30plus

Start the discussion